The newly discovered gene controls the cut-off switch for kidney inflammation leading the way to new treatment options.
The discovery about TNFAIP3 gene variants of an inflammation ‘brake’ draws researchers closer to personalized treatment for kidney disease and kidney failure patients. Researchers at the Garvan Institute of Medical Research, University of New South Wales, Sydney and Westmead Hospital, found that common genetic variants of TNFAIP3, which increase inflammation in the body, can paradoxically protect the kidneys from damage in the short term.
‘TNFAIP3 gene variants were found to alter the outcome of kidney injury through multiplex effects on inflammation and cell survival.’
“We wanted to investigate whether inherited differences in how people regulate inflammation could lead to better or worse kidney health outcomes,” says Professor Shane Grey, senior author of the paper and Head of the Transplant Immunology Lab at Garvan. “We focused on the TNFAIP3 gene, which produces a protein called A20 that acts as a ‘brake’ on inflammation. Common variants of TNFAIP3 have been linked to autoimmune disease, but their role in kidney disease was unknown. Our discovery that some genetic variants can be protective against inflammation could lead to a simple genetic test that helps predict the risk of kidney disease for patients.”
Unexpected Protective Effect of Pro-inflammatory Variant
Acute kidney injury – a sudden and rapid decline in kidney function that is in part caused by inflammation – is an important risk factor for progression to chronic kidney disease, a major health problem affecting approximately one in 10 Australians. Currently there are limited treatment options for acute kidney injury, and imprecise tools to predict who is most at risk of poor recovery or kidney failure.The team first investigated how different TNFAIP3 variants influence A20's function, finding a series of rare variants that reduced its anti-inflammatory effect. They then tested the effects of one of the variants that promotes inflammation during kidney injury in a mouse model.
“Despite increasing inflammation, this rare variant surprisingly protected the kidneys from injury. We found this protection to be due to another of A20’s functions: preventing cells from self-destructing,” says Professor Natasha Rogers, nephrologist and Head of Transplantation at Westmead Hospital, who co-led the study.
The findings are published in the journal Kidney International.
Advertisement
The study could lead to a simple genetic test to allow doctors to determine whether an individual carries a ‘hot’ version of the inflammation control gene, giving families greater certainty about their risk factors.
Advertisement
Source-Eurekalert